Dosage guide · 10 mg vial

CJC-1295 No DAC Dosage Protocol

Modified GRF 1-29 · short-acting GHRH analogue

The attributed reference protocol uses a once-daily subcutaneous amount of 100 mcg for weeks 1–2, then 150 mcg, 200 mcg and 250–300 mcg. With 3 mL of bacteriostatic water, Peak's nominal 10 mg vial is 3.33 mg/mL, so the 100 mcg starting amount is 3 units on a U-100 syringe. These are reference-site educational amounts, not a validated human schedule.

How oftenOnce daily

Starting dose100 mcg

Start = units3 units

Mix3 mL BAC water

Reviewed 25 Oct 2026 · Education only, not medical advice

CJC-1295 No DAC 10 mg vial

View on Peak Peptides

Exact Peak Peptides Australia product photo

Dosage chart How to mix Supplies Calculator About CJC-1295 No DAC References

01 · DOSAGE CHART

CJC-1295 No DAC dosage chart

Gradual daily approach · 10 mg vial + 3 mL BAC water

BAC water added

Concentration3.33 mg/mL

1 unit (U-100)33.3 mcg= 0.01 mL

How oftenOnce dailySubcutaneous injection

Peak provides illustrative concentration worksheets rather than a prescribed mix; 3 mL follows the reference protocol's water volume and makes 100 mcg equal 3 units.

CJC-1295 No DAC dosage chart for a 10 mg vial mixed with 3 mL of bacteriostatic water
Week	Daily dose	Syringe units
Weeks 1–2Start	100 mcg	3 units0.03 mL
Weeks 3–4	150 mcg	4.5 units0.045 mL
Weeks 5–6	200 mcg	6 units0.06 mL
Weeks 7–12Maintenance	250–300 mcg	7.5–9 units0.075–0.09 mL

Once daily · reference timing: bedtime · subcutaneous injection

The cited reference moves through 50 mcg steps and lists 250–300 mcg daily for weeks 7–12.

The reference describes an 8–12 week course and mentions an optional 16-week extension, but gives no separate step after week 12.

This chart copies a third-party educational protocol; it is not a product direction or a clinically established No DAC dose.

Community-reported reference amounts — CJC-1295 No DAC has no approved or clinically established human dose. Education only, not medical advice. Dose amounts adapted from CJC-1295 NO DAC 5 mg vial dosage protocol (PeptideDosages.com); units are recalculated for the vial and mix selected above.

02 · HOW TO MIX

Mixing a 10 mg vial with 3 mL of BAC water

Using a 1 mL (100-unit) insulin syringe, 3 full draws of bacteriostatic water gives 3.33 mg/mL.

1
Add the water slowly
Wipe both rubber stoppers with an alcohol swab and let them dry. Draw 3 mL of bacteriostatic water and let it run slowly down the inside of the vial wall — not straight onto the powder.
2
Swirl gently
Swirl or roll the vial gently until the powder has dissolved. Give it a few minutes to settle if needed.
3
Don't shake it
Shaking can damage the peptide and cause foaming. Gentle swirling only.
4
Check it's fully clear
Only use it once it is fully clear with no particles. Label the vial with the date and 3.33 mg/mL, then store it in the fridge at 2–8 °C.

Full illustrated reconstitution guide

03 · SUPPLIES NEEDED

What you'll need

Counts follow the dosage chart above at the highest amount in each step, using a 10 mg vial mixed with 3 mL.

Length of protocol

2CJC-1295 No DAC 10 mg vials10.5 mg needed in total

581 mL insulin syringesU-100, 27–31G · one per draw + one per vial mixed

1BAC water 10 mL bottle6 mL used for mixing

116Alcohol swabsSkin + stopper, every time

Plus an approved sharps container. Syringes and swabs are sold by Australian pharmacies — Peak Peptides and Pure Performance supply the bacteriostatic water.

CJC-1295 No DAC 10 mg vialPeak Peptides Australia

Peak Peptides Australia Bacteriostatic water 10 mL

Bacteriostatic water 10 mLPeak Peptides Australia

Pure Performance Australia Bacteriostatic water 10 mL

Bacteriostatic water 10 mLPure Performance Australia

04 · CALCULATOR

Check a different amount

Enter your vial, water and dose to see the matching syringe units.

Concentration Calculator

Labelled Vial Amount (mg)

Verified Final Liquid Volume3 mL

Amount to Evaluate (not a recommendation)

mcg

Concentration

3.33 mg/mL

(3333 mcg/mL)

Calculated Liquid Volume

0.030 mL

Equivalent U-100 volume scale position

3markings (not biological IU)

Illustration of a U-100 volume scale, not preparation or injection guidance

05 · PROTOCOL DETAILS

About CJC-1295 No DAC

Protocol overview

Starting dose: 100 mcg once daily for weeks 1–2
How it increases: 150 mcg, then 200 mcg, then 250–300 mcg daily
Frequency: Once daily
Reference timing: Bedtime
Reference duration: 8–12 weeks; the source mentions an optional 16-week extension
Common mix: 3 mL bacteriostatic water → 3.33 mg/mL from a nominal 10 mg vial

Storage

Before mixing: Keep the sealed freeze-dried vial dry and dark at 2–8 °C; Peak also describes −20 °C for long-term storage.
After mixing: Peak says to keep a BAC-water mixture upright at 2–8 °C, away from light, and use it within about 4 weeks (28 days).
Never: Do not freeze it once mixed or use it if there is persistent cloudiness, particles, unexpected colour, leakage or closure damage.

How it works

CJC-1295 No DAC is the non-DAC material Peak calls Modified GRF 1-29. FDA treats CJC-1295 free base and CJC-1295 DAC as two separate active moieties, so their pharmacokinetics and research findings should not be treated as interchangeable.

Growth hormone-releasing hormone normally activates GHRH receptors on anterior-pituitary somatotroph cells. FDA did not identify pharmacology studies of CJC-1295 free base or acetate, so effects reported for the long-acting DAC compound do not establish effects of this No DAC product.

Illustrated mechanism explainer

What the research shows

The TGA's 13 April 2026 safety advisory names CJC-1295 among unapproved peptide products; it says these products have not been evaluated by the TGA for safety, quality or effectiveness.
FDA's 2024 review says CJC-1295 free base and CJC-1295 DAC are separate active moieties, and neither is a component of an FDA-approved medicine.
The published healthy-adult CJC-1295 research comprised two randomised, placebo-controlled trials lasting 28 and 49 days, but it examined a long-acting compound rather than the No DAC product.
In that long-acting CJC-1295 research, single injections increased mean GH 2- to 10-fold for at least 6 days and mean IGF-I 1.5- to 3-fold for 9–11 days; the reported 5.8–8.1-day half-life must not be applied to No DAC.
FDA's review found 63 people exposed to CJC-1295 DAC in the reviewed studies; 46 received only one dose and the long-term human safety profile remains unknown. This is not direct No DAC safety evidence.

Reported side effects

There is no identified human clinical safety dataset for CJC-1295 free base or acetate in FDA's review, so the safety profile of this No DAC formulation is unknown.
In the long-acting DAC evidence reviewed by FDA, injection-site reactions were most common; other reported reactions included flushing-type vasodilatory reactions, headache, nausea, abdominal pain, diarrhoea, dizziness, hypotension and increased heart rate. These reports cannot provide a No DAC rate.
The TGA reports severe allergic reactions, inflammatory reactions, palpitations and other harms among reports involving unapproved peptide products; these reports are not specific proof of effects from CJC-1295 No DAC.

Important notes

CJC-1295 is an unapproved peptide product in Australia and is not a component of an FDA-approved medicine. Peak lists this vial for in-vitro laboratory research only.
Prohibited in sport at all times: WADA lists CJC-1295 among GHRH analogues under S2, peptide hormones, growth factors, related substances and mimetics.
No DAC and DAC are different active moieties. Do not apply the DAC trial's 5.8–8.1-day half-life, weekly schedules or reported outcomes to this No DAC vial.
Peak's arithmetic is based on the nominal 10 mg label claim; its linked tested-sample record reports 9.13 mg by HPLC for one sample, so label-strength calculations cannot verify every vial.
Never use a mixed vial that is cloudy or has particles in it.

Injection basics

Use a new sterile 1 mL (100-unit) U-100 insulin syringe, 27–31G, every time — never reuse or share.
Wipe the vial stopper and the skin with an alcohol swab and let both dry first.
Inject under the skin (subcutaneously) of the abdomen, thigh or upper arm, and rotate sites.
Put used syringes straight into an approved sharps container — the NDSS lists Australian disposal options.

Guidance: World Health Organization · National Diabetes Services Scheme (NDSS)

06 · QUICK ANSWERS

CJC-1295 No DAC questions

How many units is 100 mcg of CJC-1295 No DAC?

With 3 mL in a nominal 10 mg vial, the concentration is 3.33 mg/mL. A 100 mcg amount is 3 units on a U-100 syringe, or 0.03 mL; 300 mcg is 9 units, or 0.09 mL.

How much bacteriostatic water for a 10 mg CJC-1295 No DAC vial?

This guide uses 3 mL because that is the cited reference protocol's water volume. For a nominal 10 mg vial, 3 mL calculates to 3.33 mg/mL, where 1 mg is 30 units or 0.30 mL on a U-100 syringe.

How long does a 10 mg CJC-1295 No DAC vial last?

Nominally, a 10 mg vial contains 100 daily 100 mcg amounts, about 67 daily 150 mcg amounts, 50 daily 200 mcg amounts, 40 daily 250 mcg amounts or about 33 daily 300 mcg amounts. Storage limits can be shorter than those arithmetic totals.

Is CJC-1295 No DAC the same as CJC-1295 DAC?

No. FDA treats CJC-1295 free base and CJC-1295 DAC as different active moieties. The published long-acting CJC-1295 trial results and half-life therefore do not establish a dose, half-life or outcome for the No DAC product.

07 · SOURCES